PROTAC RIPK degrader-6 is utilized in the field of targeted protein degradation, specifically for degrading Receptor-Interacting Serine/Threonine-Protein Kinase (RIPK) proteins. Its application is primarily in research and drug development, where it helps in studying the role of RIPK in cellular processes such as inflammation, cell death, and immune response. By degrading RIPK proteins, it aids in understanding their function and potential as therapeutic targets in diseases like cancer, neurodegenerative disorders, and inflammatory conditions. This compound is also used to validate the efficacy of PROTAC technology in selectively eliminating disease-causing proteins, paving the way for novel therapeutic strategies.